Policy

Genomic data can have a significant effect on other areas of society. Insurance premiums, familial impact, identification. As we enter the genomic era, policy will need to reflect these new considerations.

Festival of Genomics 2019 – The State of Genomics Today

The introduction of multi-omic research, the advancement of AI and machine learning to improve nearly every aspect of sequencing and data analysis, are just some of the big changes that will only become more prevalent in the future. We spoke to Angela Douglas MBE, Scientific Director of Genetics Laboratories at Liverpool Women’s Hospital, for her opinions on the changing nature of genomics and the trends to watch out for.

UCB to Invest £1 Billion in UK R&D

Multinational biopharmaceutical company UCB has agreed to invest £1 billion in UK research and development (R&D), the government has announced in its latest Life Sciences Sector Deal. In the deal, £75 million will be invested into the development of new AI driven diagnostic tests while £50 million will be invested in digital pathology programmes and £37.5 million into regional digital innovation hubs.

ClinGen Gets FDA Recognition

The US Food and Drug Administration (FDA) announced ClinGen as the first FDA-designated public genetic variants repository this week.

Scientists Denied Access to Symposium Raise UK Immigration Concerns

The scientific community has raised concerns about the state of UK immigration after a number of academics attending the Global Symposium on Health Systems Research were denied access to the country recently. At least 10 of the 200 attendees were affected by the policy, with arguments raised that such policies could impact academic co-operation.

Molecular Diagnostics Report

Read our report on all things Molecular Diagnostics, including some great contributed articles. Need to know about liquid biopsies? Want to know what the current regulatory landscape looks like? Then you’ve come to the right place.